RU2010149999A - Средство, предназначенное для лечения и/или профилактики аутоиммунного заболевания регуляторных т-клеток - Google Patents
Средство, предназначенное для лечения и/или профилактики аутоиммунного заболевания регуляторных т-клеток Download PDFInfo
- Publication number
- RU2010149999A RU2010149999A RU2010149999/15A RU2010149999A RU2010149999A RU 2010149999 A RU2010149999 A RU 2010149999A RU 2010149999/15 A RU2010149999/15 A RU 2010149999/15A RU 2010149999 A RU2010149999 A RU 2010149999A RU 2010149999 A RU2010149999 A RU 2010149999A
- Authority
- RU
- Russia
- Prior art keywords
- hil
- use according
- mutein
- antibodies
- fragment
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title claims abstract 6
- 230000002265 prevention Effects 0.000 title claims abstract 4
- 210000003289 regulatory T cell Anatomy 0.000 title claims 4
- 101100506090 Caenorhabditis elegans hil-2 gene Proteins 0.000 claims abstract 12
- 239000012634 fragment Substances 0.000 claims abstract 9
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims abstract 6
- 108010036949 Cyclosporine Proteins 0.000 claims abstract 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract 6
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims abstract 6
- 229960002170 azathioprine Drugs 0.000 claims abstract 6
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims abstract 6
- 229960001265 ciclosporin Drugs 0.000 claims abstract 6
- 229940079593 drug Drugs 0.000 claims abstract 6
- 239000003814 drug Substances 0.000 claims abstract 6
- 229960003444 immunosuppressant agent Drugs 0.000 claims abstract 6
- 230000001861 immunosuppressant effect Effects 0.000 claims abstract 6
- 239000003018 immunosuppressive agent Substances 0.000 claims abstract 6
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims abstract 6
- 229960000310 isoleucine Drugs 0.000 claims abstract 6
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 claims abstract 4
- 102000055277 human IL2 Human genes 0.000 claims abstract 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims abstract 3
- 239000004475 Arginine Substances 0.000 claims abstract 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims abstract 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims abstract 3
- 229930105110 Cyclosporin A Natural products 0.000 claims abstract 3
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims abstract 3
- 102000006395 Globulins Human genes 0.000 claims abstract 3
- 108010044091 Globulins Proteins 0.000 claims abstract 3
- 239000004471 Glycine Substances 0.000 claims abstract 3
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims abstract 3
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims abstract 3
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims abstract 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims abstract 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims abstract 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims abstract 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract 3
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims abstract 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims abstract 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims abstract 3
- 229960002964 adalimumab Drugs 0.000 claims abstract 3
- 235000001014 amino acid Nutrition 0.000 claims abstract 3
- 150000001413 amino acids Chemical group 0.000 claims abstract 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract 3
- 235000009582 asparagine Nutrition 0.000 claims abstract 3
- 229960001230 asparagine Drugs 0.000 claims abstract 3
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims abstract 3
- 235000003704 aspartic acid Nutrition 0.000 claims abstract 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims abstract 3
- 229960004669 basiliximab Drugs 0.000 claims abstract 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims abstract 3
- 102220357126 c.58G>T Human genes 0.000 claims abstract 3
- 229960004397 cyclophosphamide Drugs 0.000 claims abstract 3
- 229930182912 cyclosporin Natural products 0.000 claims abstract 3
- 229960002806 daclizumab Drugs 0.000 claims abstract 3
- 229960005167 everolimus Drugs 0.000 claims abstract 3
- 229960000556 fingolimod Drugs 0.000 claims abstract 3
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 claims abstract 3
- 239000003862 glucocorticoid Substances 0.000 claims abstract 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract 3
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims abstract 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims abstract 3
- 229960000598 infliximab Drugs 0.000 claims abstract 3
- 229960000485 methotrexate Drugs 0.000 claims abstract 3
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims abstract 3
- 229960004866 mycophenolate mofetil Drugs 0.000 claims abstract 3
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 claims abstract 3
- 229940083410 myfortic Drugs 0.000 claims abstract 3
- 229940096112 prednisol Drugs 0.000 claims abstract 3
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims abstract 3
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims abstract 3
- 229960002930 sirolimus Drugs 0.000 claims abstract 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims abstract 3
- 238000006467 substitution reaction Methods 0.000 claims abstract 3
- 229960001967 tacrolimus Drugs 0.000 claims abstract 3
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims abstract 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims abstract 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims abstract 2
- 208000011231 Crohn disease Diseases 0.000 claims abstract 2
- 208000007882 Gastritis Diseases 0.000 claims abstract 2
- 201000004681 Psoriasis Diseases 0.000 claims abstract 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims abstract 2
- 208000023652 chronic gastritis Diseases 0.000 claims abstract 2
- 201000010099 disease Diseases 0.000 claims abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 2
- 229940126601 medicinal product Drugs 0.000 claims abstract 2
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract 2
- 206010028417 myasthenia gravis Diseases 0.000 claims abstract 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract 2
- 230000015572 biosynthetic process Effects 0.000 claims 3
- 230000001363 autoimmune Effects 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 claims 1
- 102100036465 Autoimmune regulator Human genes 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 208000001204 Hashimoto Disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 101000928549 Homo sapiens Autoimmune regulator Proteins 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 208000025174 PANDAS Diseases 0.000 claims 1
- 208000021155 Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 208000032384 Severe immune-mediated enteropathy Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000001974 autoimmune enteropathy Diseases 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464456—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
- A61K39/464491—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
- A61K39/464492—Glycoprotein 100 [Gp100]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55533—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
Abstract
1. Применение мутеина человеческого интерлейкина-2 (мутеин hIL-2) или его фрагмента, пронумерованного в соответствии с hIL-2 дикого типа и имеющего аминокислотную замену по меньшей мере в одном из положений 20, 88 или 126, для приготовления лекарственного средства, предназначенного для лечения и/или профилактики аутоиммунного заболевания. ! 2. Применение по п.1, отличающееся тем, что осуществляют замену аспарагина в положении 88 на аргинин (hIL-2-N88R), или на глицин (hIL-2-N88G), или на изолейцин (hIL-2-N88I). ! 3. Применение по п.1 или 2, отличающееся тем, что осуществляют замену аспарагиновой кислоты в положении 20 на гистидин (hIL-2-D20H), или на изолейцин (hIL-2-D20H), или на тирозин (hIL-2-D20Y). ! 4. Применение по п.1, отличающееся тем, что осуществляют замену глутамина в положении 126 на лейцин (hIL-2-Q126L). ! 5. Применение по п.1, отличающееся тем, что лекарственное средство дополнительно содержит иммунодепрессант. ! 6. Применение по п.5, отличающееся тем, что иммунодепрессант выбран из группы, включающей: глюкокортикоид, в том числе декортин, преднизол; азатиоприн; циклоспорин А; микофенолята мофетил; такролимус; глобулин к Т-лимфоцитам, антитела к CD3, включая муромонаб; антитела к CD25, включая базиликсимаб и даклизумаб; антитела к TNF-α, включая инфликсимаб и адалимумаб; азатиоприн; метотрексат; циклоспорин; сиролимус; эверолимус; финголимод; селлцепт (CellCept); мифортик и циклофосфамид. ! 7. Применение по п.1, отличающееся тем, что аутоиммунное заболевание выбрано из группы, включающей: сахарный диабет типа I, ревматоидный артрит, рассеянный склероз, хронический гастрит, болезнь Крона, базедову болезнь, болезнь Бехтерева, псориаз, тяжелую псевдопаралитическую миастению, аутои�
Claims (18)
1. Применение мутеина человеческого интерлейкина-2 (мутеин hIL-2) или его фрагмента, пронумерованного в соответствии с hIL-2 дикого типа и имеющего аминокислотную замену по меньшей мере в одном из положений 20, 88 или 126, для приготовления лекарственного средства, предназначенного для лечения и/или профилактики аутоиммунного заболевания.
2. Применение по п.1, отличающееся тем, что осуществляют замену аспарагина в положении 88 на аргинин (hIL-2-N88R), или на глицин (hIL-2-N88G), или на изолейцин (hIL-2-N88I).
3. Применение по п.1 или 2, отличающееся тем, что осуществляют замену аспарагиновой кислоты в положении 20 на гистидин (hIL-2-D20H), или на изолейцин (hIL-2-D20H), или на тирозин (hIL-2-D20Y).
4. Применение по п.1, отличающееся тем, что осуществляют замену глутамина в положении 126 на лейцин (hIL-2-Q126L).
5. Применение по п.1, отличающееся тем, что лекарственное средство дополнительно содержит иммунодепрессант.
6. Применение по п.5, отличающееся тем, что иммунодепрессант выбран из группы, включающей: глюкокортикоид, в том числе декортин, преднизол; азатиоприн; циклоспорин А; микофенолята мофетил; такролимус; глобулин к Т-лимфоцитам, антитела к CD3, включая муромонаб; антитела к CD25, включая базиликсимаб и даклизумаб; антитела к TNF-α, включая инфликсимаб и адалимумаб; азатиоприн; метотрексат; циклоспорин; сиролимус; эверолимус; финголимод; селлцепт (CellCept); мифортик и циклофосфамид.
7. Применение по п.1, отличающееся тем, что аутоиммунное заболевание выбрано из группы, включающей: сахарный диабет типа I, ревматоидный артрит, рассеянный склероз, хронический гастрит, болезнь Крона, базедову болезнь, болезнь Бехтерева, псориаз, тяжелую псевдопаралитическую миастению, аутоиммунный гепатит, APECED, синдром Черджа-Стросс, неспецифический язвенный колит, гломерулонефрит, синдром Гийена-Барре, тироидит Хашимото, лихен-склероз, системную красную волчанку, PANDAS, ревматическую лихорадку, саркоидоз, синдром Шегрена, синдром «негнущегося человека», склеродерму, грануломатоз Вегенера, витилиго, аутоиммунную энтеропатию, синдром Гудпасчера, дерматомиозит, полимиозит, аутоиммунную аллергию, астму и аутоиммунную реакцию после трансплантаций органов.
8. Применение по п.7, отличающееся тем, что лекарственное средство содержит фармацевтически приемлемый носитель.
9. Лекарственное средство, предназначенное для лечения и/или профилактики аутоиммунного заболевания, отличающееся тем, что содержит мутеин hIL-2 или его фрагмент, предназначенный для применения по одному из пп.1-10.
10. Применение мутеина человеческого интерлейкина-2 (мутеин hIL-2) или его фрагмента, пронумерованного в соответствии с hIL-2 дикого типа и имеющего аминокислотную замену по меньшей мере в одном из положений 20, 88 или 126, для получения средства, предназначенного для образования регуляторных Т-клеток (TReg) в живом организме.
11. Применение по п.10, отличающееся тем, что осуществляют замену аспарагина в положении 88 на аргинин (hIL-2-N88R), или на глицин (hIL-2-N88G), или на изолейцин (hIL-2-N88I).
12. Применение по п.10 или 11, отличающееся тем, что осуществляют замену аспарагиновой кислоты в положении 20 на гистидин (hIL-2-D20H), или на изолейцин (hIL-2-D20H), или на тирозин (hIL-2-D20Y).
13. Применение по п.10, отличающееся тем, что осуществляют замену глутамина в положении 126 на лейцин (hIL-2-Q126L).
14. Применение по п.12, отличающееся тем, что средство представляет собой лекарственное средство и содержит фармацевтически приемлемый носитель.
15. Применение по п.14, отличающееся тем, что лекарственное средство дополнительно содержит иммунодепрессант.
16. Применение по п.15, отличающееся тем, что иммунодепрессант выбран из группы, включающей: глюкокортикоид, в том числе декортин, преднизол; азатиоприн; циклоспорин А; микофенолята мофетил; такролимус; глобулин к Т-лимфоцитам, антитела к CD3, включая муромонаб; антитела к CD25, включая базиликсимаб и даклизумаб; антитела к TNF-α, включая инфликсимаб и адалимумаб; азатиоприн; метотрексат; циклоспорин; сиролимус; эверолимус; финголимод; селлцепт; мифортик и циклофосфамид.
17. Средство, предназначенное для образования регуляторных Т-клеток (TReg) в живом организме, отличающееся тем, что содержит мутеин hIL-2 или его фрагмент, предназначенный для применения по одному из пп.10-16.
18. Способ образования регуляторных Т-клеток (TReg) in vitro, заключающийся в том, что осуществляют следующие стадии, на которых:
(а) создают мутеин человеческого интерлейкина 2 (мутеин hIL-2) или его фрагмент,
(б) приводят в контакт мутеин hIL-2 или его фрагмент с мононуклеарными клетками периферической крови (РВМС) и
(в) при необходимости повторяют стадии (а) и (б), отличающийся тем, что мутеин hIL-2 или его фрагмент представляет собой мутеин hIL-2 или его фрагмент, предназначенный для применения по одному из пп.10-16.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102008023820.1 | 2008-05-08 | ||
| DE102008023820A DE102008023820A1 (de) | 2008-05-08 | 2008-05-08 | Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen |
| PCT/EP2009/003076 WO2009135615A2 (de) | 2008-05-08 | 2009-04-28 | Mittel zur behandlung und/oder prophylaxe einer autoimmunerkrankung und zur bildung von regulatorischen t-zellen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2010149999A true RU2010149999A (ru) | 2012-06-20 |
| RU2531936C2 RU2531936C2 (ru) | 2014-10-27 |
Family
ID=41152787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010149999/15A RU2531936C2 (ru) | 2008-05-08 | 2009-04-28 | Средство, предназначенное для лечения и/или профилактики аутоиммунного заболевания и для образования регуляторных т-клеток |
Country Status (28)
| Country | Link |
|---|---|
| US (4) | US20110150826A1 (ru) |
| EP (1) | EP2288372B1 (ru) |
| JP (2) | JP5651583B2 (ru) |
| KR (3) | KR101554056B1 (ru) |
| CN (2) | CN110935025A (ru) |
| AR (1) | AR071756A1 (ru) |
| AT (1) | ATE544465T1 (ru) |
| AU (1) | AU2009244039B2 (ru) |
| BR (1) | BRPI0912411B8 (ru) |
| CA (1) | CA2723761C (ru) |
| CL (1) | CL2009001099A1 (ru) |
| CY (1) | CY1112469T1 (ru) |
| DE (1) | DE102008023820A1 (ru) |
| DK (1) | DK2288372T3 (ru) |
| ES (1) | ES2378957T3 (ru) |
| HR (1) | HRP20120296T1 (ru) |
| IL (3) | IL209128A (ru) |
| MX (1) | MX2010012214A (ru) |
| PE (1) | PE20091967A1 (ru) |
| PL (1) | PL2288372T3 (ru) |
| PT (1) | PT2288372E (ru) |
| RU (1) | RU2531936C2 (ru) |
| SI (1) | SI2288372T1 (ru) |
| TW (1) | TWI510622B (ru) |
| UA (1) | UA102099C2 (ru) |
| UY (1) | UY31816A (ru) |
| WO (1) | WO2009135615A2 (ru) |
| ZA (1) | ZA201008129B (ru) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102008023820A1 (de) | 2008-05-08 | 2009-11-12 | Aicuris Gmbh & Co. Kg | Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen |
| ES2825173T3 (es) | 2009-01-21 | 2021-05-14 | Amgen Inc | Composiciones y métodos de tratamiento de enfermedades inflamatorias y autoinmunitarias |
| US11090363B2 (en) | 2009-07-10 | 2021-08-17 | University of Pittsburgh—of the Commonwealth System of Higher Education | Vasoactive intestinal peptide release from microparticles |
| US8846098B2 (en) | 2009-07-10 | 2014-09-30 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Artificial cell constructs for cellular manipulation |
| CU23734A1 (es) * | 2009-11-27 | 2011-11-15 | Centro Inmunologia Molecular | Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas |
| WO2012012737A2 (en) * | 2010-07-23 | 2012-01-26 | The University Of Toledo | Stable tregs and related materials and methods |
| CU23923B1 (es) * | 2010-11-12 | 2013-07-31 | Ct De Inmunología Molecular | Polipéptidos derivados de la il-2 con actividad agonista |
| BR112013023151A2 (pt) | 2011-03-11 | 2020-09-15 | Assistance Publique - Hôpitaux De Paris | interleucina-2 para uso no tratamento de desordem auto-imune, !muno-relacionada ou inflamatória e método para determinar se um regime ou dose de il-2 tem de ser modificado |
| KR102220006B1 (ko) | 2011-03-11 | 2021-02-24 | 아시스땅스 퍼블리끄-오삐또 드 빠리 | 자가면역 - 관련 또는 염증성 장애를 치료하기 위한 저용량 ｉｌ２ 의 용도 |
| US20140044675A1 (en) | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
| WO2014093118A1 (en) | 2012-12-11 | 2014-06-19 | Albert Einstein College Of Medicine Of Yeshiva University | Methods for high throughput receptor:ligand identification |
| CA2931114A1 (en) | 2014-02-06 | 2015-08-13 | F. Hoffmann-La Roche Ag | Interleukin-2 fusion proteins and uses thereof |
| SI3180020T1 (sl) | 2014-08-11 | 2019-04-30 | Delinia, Inc. | Modificirane variante IL-2, ki selektivno aktivirajo regulatorne celice T, za zdravljenje avtoimunih bolezni |
| TN2017000432A1 (en) * | 2015-04-10 | 2019-04-12 | Amgen Inc | Interleukin-2 muteins for the expansion of t-regulatory cells |
| US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| CN109071623B (zh) * | 2016-05-04 | 2022-05-27 | 美国安进公司 | 用于扩增t调节性细胞的白细胞介素-2突变蛋白 |
| BR112018073606A2 (pt) | 2016-05-18 | 2019-02-26 | Cue Biopharma, Inc. | polipeptídeos multiméricos moduladores de células t e métodos de uso dos mesmos |
| JP2019522466A (ja) | 2016-05-18 | 2019-08-15 | アルバート アインシュタイン カレッジ オブ メディシン，インコーポレイティド | 変異ｐｄ−ｌ１ポリペプチド、ｔ細胞調節多量体ポリペプチド、及びそれらの使用方法 |
| SG11201903882VA (en) | 2016-11-08 | 2019-05-30 | Delinia Inc | Il-2 variants for the treatment of autoimmune diseases |
| CN116970061A (zh) | 2016-12-22 | 2023-10-31 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
| WO2018129474A1 (en) | 2017-01-09 | 2018-07-12 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| CN110520438A (zh) * | 2017-02-03 | 2019-11-29 | 匹兹堡大学联邦系统高等教育 | 溶瘤病毒疗法 |
| EP3596108A4 (en) | 2017-03-15 | 2020-12-23 | Pandion Operations, Inc. | TARGETED IMMUNOTOLERANCE |
| EP3596118A4 (en) | 2017-03-15 | 2021-04-07 | Cue Biopharma, Inc. | PROCESSES FOR MODULATING AN IMMUNE RESPONSE |
| JP2020521452A (ja) | 2017-05-24 | 2020-07-27 | パンディオン・セラピューティクス・インコーポレイテッド | 標的化免疫寛容 |
| KR102164417B1 (ko) | 2017-09-15 | 2020-10-13 | 주식회사 카인사이언스 | 치료제로서의 펩타이드의 용도 |
| KR102219926B1 (ko) | 2017-09-15 | 2021-02-25 | 주식회사 카인사이언스 | 치료제로서의 펩타이드의 용도 |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US11319355B2 (en) | 2017-12-19 | 2022-05-03 | Xencor, Inc. | Engineered IL-2 Fc fusion proteins |
| TW201930345A (zh) * | 2017-12-27 | 2019-08-01 | 日商協和醱酵麒麟有限公司 | Il-2改型體 |
| EP3737689A4 (en) | 2018-01-09 | 2021-12-01 | Cue Biopharma, Inc. | MULTIMERIC T CELL-MODULATING POLYPEPTIDES AND METHOD OF USING THEREOF |
| WO2019158764A1 (en) | 2018-02-16 | 2019-08-22 | Iltoo Pharma | Use of interleukin 2 for treating sjögren's syndrome |
| AR115024A1 (es) | 2018-03-28 | 2020-11-18 | Bristol Myers Squibb Co | PROTEÍNAS DE FUSIÓN INTERLEUCINA-2 / RECEPTOR a DE INTERLEUCINA-2 Y MÉTODOS DE USO |
| WO2020007937A1 (en) | 2018-07-03 | 2020-01-09 | Iltoo Pharma | Use of interleukin-2 for treating systemic sclerosis |
| WO2020035482A1 (en) | 2018-08-13 | 2020-02-20 | Iltoo Pharma | Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof |
| WO2020125743A1 (zh) | 2018-12-21 | 2020-06-25 | 江苏恒瑞医药股份有限公司 | 一种人白细胞介素2变体或其衍生物 |
| WO2020163782A2 (en) | 2019-02-08 | 2020-08-13 | The Uab Research Foundation | Immunotherapy for the treatment and prevention of inflammatory bowel disease |
| EP3958887B1 (en) * | 2019-04-23 | 2023-11-01 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Medical uses for inducing or restoring immune tolerance |
| WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| JP2022533702A (ja) | 2019-05-20 | 2022-07-25 | パンディオン・オペレーションズ・インコーポレイテッド | ＭＡｄＣＡＭ標的化免疫寛容 |
| CN110642934B (zh) * | 2019-09-10 | 2022-08-23 | 中国医学科学院北京协和医院 | 靶向调节t细胞的长效白介素-2及其在治疗自身免疫病中的应用 |
| CA3159468A1 (en) | 2019-12-12 | 2021-06-17 | David Klatzmann | Interleukin 2 chimeric constructs |
| CA3166509A1 (en) | 2020-01-14 | 2021-07-22 | Synthekine, Inc. | Biased il2 muteins methods and compositions |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| CA3169949A1 (en) | 2020-05-12 | 2021-11-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| KR102219927B1 (ko) | 2020-05-20 | 2021-02-24 | 주식회사 카인사이언스 | 치료제로서의 펩타이드의 용도 |
| US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| KR102219928B1 (ko) | 2020-06-26 | 2021-02-24 | 주식회사 카인사이언스 | 치료제로서의 펩타이드의 용도 |
| JP2023548311A (ja) | 2020-10-29 | 2023-11-16 | ブリストル－マイヤーズ スクイブ カンパニー | 疾患の治療のための融合タンパク質 |
| AU2021391924A1 (en) * | 2020-12-04 | 2023-06-22 | The General Hospital Corporation | Methods of using interleukin-2 agents |
| CN112843222B (zh) * | 2021-01-21 | 2023-01-31 | 暨南大学 | Ankrd22蛋白在制备治疗或延缓自身免疫性疾病的产品中的应用 |
| WO2023005680A1 (zh) | 2021-07-30 | 2023-02-02 | 西安龙腾景云生物科技有限公司 | 一种人白细胞介素2变体及其用途 |
| IL311883A (en) | 2021-10-06 | 2024-06-01 | Assist Publique H?Pitaux De Paris | Interleukin 2 chimeric constructs with targeted specificity for inflammatory tissues |
| WO2024056154A1 (en) | 2022-09-12 | 2024-03-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Interleukin-2 for use in treating autism spectrum disorder |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DZ2788A1 (fr) * | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
| US6955807B1 (en) * | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
| US6348192B1 (en) | 1999-05-11 | 2002-02-19 | Bayer Corporation | Interleukin-2 mutein expressed from mammalian cells |
| US6689353B1 (en) | 2000-06-28 | 2004-02-10 | Bayer Pharmaceuticals Corporation | Stabilized interleukin 2 |
| US20060057651A1 (en) * | 2000-12-08 | 2006-03-16 | Bowdish Katherine S | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| EP1476180A4 (en) * | 2001-08-13 | 2005-04-20 | Univ Southern California | INTERLEUKIN-2 MUTANTS WITH REDUCED TOXICITY |
| EP2354791A1 (en) * | 2001-12-04 | 2011-08-10 | Merck Patent GmbH | Immunocytokines with modulated selectivity |
| US20060121029A1 (en) * | 2002-08-30 | 2006-06-08 | Hiroshi Shiku | Method and composition for regulating the activity of regulatory t cells |
| JP2006506386A (ja) * | 2002-10-22 | 2006-02-23 | ワラタ ファーマシューティカルズ， インコーポレイテッド | 糖尿病の処置 |
| CA2552891A1 (en) * | 2004-01-08 | 2005-08-04 | Regents Of The University Of California | Regulatory t cells suppress autoimmunity |
| US20060234205A1 (en) * | 2004-03-05 | 2006-10-19 | Chiron Corporation | In vitro test system for predicting patient tolerability of therapeutic agents |
| DE202005001888U1 (de) * | 2005-02-07 | 2005-07-28 | Chiron Corp., Emeryville | Zusammensetzung, die Interleukin-2 und Natriumdodecylsulfat umfaßt |
| US8906356B2 (en) | 2007-11-05 | 2014-12-09 | Massachusetts Institute Of Technology | Mutant interleukin-2 (IL-2) polypeptides |
| DE102008023820A1 (de) | 2008-05-08 | 2009-11-12 | Aicuris Gmbh & Co. Kg | Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen |
-
2008
- 2008-05-08 DE DE102008023820A patent/DE102008023820A1/de not_active Withdrawn
-
2009
- 2009-04-28 CN CN201911154127.8A patent/CN110935025A/zh active Pending
- 2009-04-28 RU RU2010149999/15A patent/RU2531936C2/ru not_active IP Right Cessation
- 2009-04-28 SI SI200930229T patent/SI2288372T1/sl unknown
- 2009-04-28 AT AT09741834T patent/ATE544465T1/de active
- 2009-04-28 CA CA2723761A patent/CA2723761C/en not_active Expired - Fee Related
- 2009-04-28 EP EP09741834A patent/EP2288372B1/de active Active
- 2009-04-28 CN CN2009801266762A patent/CN102088996A/zh active Pending
- 2009-04-28 PL PL09741834T patent/PL2288372T3/pl unknown
- 2009-04-28 AU AU2009244039A patent/AU2009244039B2/en not_active Ceased
- 2009-04-28 UA UAA201014444A patent/UA102099C2/ru unknown
- 2009-04-28 BR BRPI0912411A patent/BRPI0912411B8/pt not_active IP Right Cessation
- 2009-04-28 DK DK09741834.7T patent/DK2288372T3/da active
- 2009-04-28 WO PCT/EP2009/003076 patent/WO2009135615A2/de active Application Filing
- 2009-04-28 KR KR1020107026580A patent/KR101554056B1/ko active IP Right Grant
- 2009-04-28 ES ES09741834T patent/ES2378957T3/es active Active
- 2009-04-28 PT PT09741834T patent/PT2288372E/pt unknown
- 2009-04-28 KR KR1020157013806A patent/KR101687506B1/ko active IP Right Grant
- 2009-04-28 KR KR1020167020193A patent/KR20160092048A/ko not_active Application Discontinuation
- 2009-04-28 MX MX2010012214A patent/MX2010012214A/es active IP Right Grant
- 2009-04-28 JP JP2011507816A patent/JP5651583B2/ja not_active Expired - Fee Related
- 2009-05-07 PE PE2009000635A patent/PE20091967A1/es not_active Application Discontinuation
- 2009-05-07 CL CL2009001099A patent/CL2009001099A1/es unknown
- 2009-05-07 TW TW098115067A patent/TWI510622B/zh not_active IP Right Cessation
- 2009-05-07 UY UY0001031816A patent/UY31816A/es not_active Application Discontinuation
- 2009-05-08 AR ARP090101665A patent/AR071756A1/es not_active Application Discontinuation
-
2010
- 2010-11-04 IL IL209128A patent/IL209128A/en active IP Right Grant
- 2010-11-08 US US12/941,885 patent/US20110150826A1/en not_active Abandoned
- 2010-11-12 ZA ZA2010/08129A patent/ZA201008129B/en unknown
-
2012
- 2012-03-08 CY CY20121100236T patent/CY1112469T1/el unknown
- 2012-04-03 HR HR20120296T patent/HRP20120296T1/hr unknown
-
2014
- 2014-09-08 JP JP2014182422A patent/JP2015038084A/ja active Pending
-
2015
- 2015-06-26 US US14/752,726 patent/US9616105B2/en not_active Expired - Fee Related
-
2017
- 2017-02-05 IL IL250435A patent/IL250435A0/en unknown
- 2017-02-22 US US15/439,866 patent/US20170173117A1/en not_active Abandoned
- 2017-02-22 US US15/439,845 patent/US10086046B2/en not_active Expired - Fee Related
- 2017-08-02 IL IL253790A patent/IL253790A0/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010149999A (ru) | Средство, предназначенное для лечения и/или профилактики аутоиммунного заболевания регуляторных т-клеток | |
| Picchianti Diamanti et al. | Cytokine release syndrome in COVID-19 patients, a new scenario for an old concern: the fragile balance between infections and autoimmunity | |
| Wu et al. | Developmental and functional control of natural killer cells by cytokines | |
| Maury et al. | Correlation of serum cytokine levels with haematological abnormalities in human immunodeficiency virus infection | |
| Ricci et al. | Innate immune response to SARS-CoV-2 infection: From cells to soluble mediators | |
| Venkatesha et al. | Cytokine-modulating strategies and newer cytokine targets for arthritis therapy | |
| Waldmann | The IL-2/IL-15 receptor systems: targets for immunotherapy | |
| Waldmann | Targeting the interleukin-15/interleukin-15 receptor system in inflammatory autoimmune diseases | |
| MX2007009466A (es) | Anticuerpos monoclonales de anti-interferon alfa y metodos para su uso. | |
| Montaño et al. | Theophylline: Old drug in a new light, application in COVID-19 through computational studies | |
| CN114380891B (zh) | 具有抗炎症活性的肽及其用途 | |
| Jin et al. | The inflammatory Th 17 subset in immunity against self and non-self antigens | |
| Wu et al. | Stem cell mobilizers targeting chemokine receptor CXCR4: renoprotective application in acute kidney injury | |
| Huber et al. | A nut for every bolt: subunit-selective inhibitors of the immunoproteasome and their therapeutic potential | |
| CN1142186A (zh) | 用白介素-10激活外周血单核细胞的细胞溶解活性 | |
| Szumilas et al. | Current status regarding immunosuppressive treatment in patients after renal transplantation | |
| Laranjeira et al. | Human bone marrow mesenchymal Stromal/Stem cells regulate the Proinflammatory response of Monocytes and myeloid dendritic cells from patients with rheumatoid arthritis | |
| Meng et al. | Potential for jaktinib hydrochloride to treat cytokine storms in patients with COVID-19 | |
| RU2007134338A (ru) | Полиэпитопный пептид иммунологической и противоопухолевой активностью, полученный из тимидилатсинтазы | |
| Kaur et al. | Role of cytokines as immunomodulators | |
| CN1973898A (zh) | 一种含p28分子或其基因的医药制剂 | |
| CN109803681B (zh) | 用于治疗免疫病症的免疫抑制组合物 | |
| CN1911958A (zh) | 一种抑制p38激酶活性的多肽及其应用 | |
| Huang et al. | Interleukins in platelet biology: Unraveling the complex regulatory network | |
| Behfar et al. | Genes affecting in cytokine storm as therapeutic targets in COVID-19 infection. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20200429 |